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Abstract 
Purpose: We investigated the associations of ten previously identified high risk molecular lipid 
species and three ceramide ratios with the occurrence of major adverse cardiac events (MACE) during a 
median follow-up of 4.7 years in patients with coronary artery disease (CAD).  
Methods: Between 2008 and 2011, 581 patients underwent diagnostic coronary angiography or 
percutaneous coronary intervention for stable angina pectoris (SAP) or acute coronary syndrome (ACS). 
Blood was drawn prior to the index procedure and lipid species were determined. The primary endpoint 
was the occurrence of MACE, comprising all-cause mortality, nonfatal ACS or unplanned coronary 
revascularization. The secondary endpoint comprised all-cause mortality or nonfatal ACS. 
Results: During a median follow-up of 4.7 [IQR: 4.2- 5.6] years, 155 patients (27%) had MACE. 
In multivariable analyses, Cer(d18:1/16:0) concentration was associated with MACE (HR 2.32; 95% CI 
[1.09-4.96] per ln(pmol/mL) p= 0.030) after adjustment for cardiac risk factors, clinical presentation, 
statin use at baseline and admission non-HDL cholesterol level. Furthermore, after multivariable 
adjustment, concentrations of Cer(d18:1/16:0), Cer(d18:1/20:0), Cer(d18:1/24:1) and their ratios to 
Cer(d18:1/24:0) were associated with the composite endpoint death or nonfatal ACS.  
Conclusion: Altogether, the circulating ceramide lipids we investigated here are associated with 
adverse cardiac outcome during long-term follow-up independent of clinical risk factors.   
 
 
 
Keywords 
Lipidomics; Ceramides; Heart; Atherosclerosis; Vascular biology; Follow-up; Prognosis. 
 
 
 
 
 by guest, on Septem
ber 12, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
- 3 - 
 
Introduction 
Established lipid markers such as total cholesterol, low-density lipoprotein (LDL) cholesterol, 
triglycerides (TG)  and high-density lipoprotein (HDL) cholesterol have long formed the cornerstone of 
lipid-based risk stratification in coronary artery disease (CAD) (1-4). However these measures alone do 
not fully capture the complexity of the altered lipid metabolism in cardiovascular disease (2), and this 
may be the reason that they fail to identify a substantial proportion of patients at high risk for coronary 
events (1).  
Lipidomics is a systems-based study of all lipids (5) that has been defined as the full 
characterization of lipid molecular species and their biological roles (6). In its most advanced form, 
lipidomics is able to quantify hundreds of diverse molecular lipid species across multiple lipid classes 
such as sphingolipids, phospholipids, sterol esters, and acylglycerols, (7) many of which play an integral 
role in modulation of biological function such as formation of cellular membranes, energy storage and 
cell signaling (8, 9). Since lipidomics provides such detailed lipid profiles, it may further improve risk 
stratification of CAD patients and provide novel mechanistic insights into CAD (4). 
In line with this hypothesis, we have recently performed lipidomics in the Ludwigshafen Risk and 
Cardiovascular Health (LURIC) study and identified several molecular lipid species that are associated 
with fatal events in patients with CAD (1). In the current study, we hypothesized that these ten previously 
identified high risk molecular lipid species and three ceramide ratios are associated with occurrence of 
major adverse cardiac events (MACE) during long-term follow-up.  
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Methods 
Study population and design 
The design of the European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis (ATHEROREMO) has been described elsewhere in detail (10). In brief, 
from 2008 until 2011, 581 patients with an indication for diagnostic coronary angiography (CAG) and/or 
percutaneous coronary intervention (PCI) due to stable angina pectoris (SAP) or acute coronary syndrome 
(ACS) were included at the Erasmus MC, Rotterdam, the Netherlands. Prior to the CAG or PCI procedure 
blood samples were collected from the arterial sheath and were transported to the clinical laboratory of 
Erasmus MC within 2h after blood collection for storage at a temperature of −80 °C. All included patients 
were 18 years or older. The ATHEROREMO study was approved by the medical ethics committee of 
Erasmus MC and was performed in accordance with the criteria described in the declaration of Helsinki. 
Written informed consent was obtained from all included patients. 
 
Serum concentrations of cholesterol and triglycerides  
Levels of total cholesterol, LDL cholesterol, HDL cholesterol and TG were measured in the clinical 
laboratory of the Erasmus MC in serum samples using Roche/Hitachi cobas c 701/702 analyzer (Roche 
Diagnostics, Indianapolis, USA) on the Cobas 8000 modular analyzer platform (Roche Diagnostics, 
Indianapolis, USA).  
 
Plasma concentrations of molecular lipids 
Molecular lipids and lipid ratios that were previously found to be associated with fatal cardiovascular 
outcome at a p <0.05 level in the LURIC study were selected for evaluation in the current study(1). These 
included cholesteryl esters (CE): CE 14:0, CE 18:3, CE 20:4, CE 20:5, CE 22:5; ceramides (Cer): 
Cer(d18:1/16:0), Cer(d18:1/20:0), Cer(d18:1/24:0), Cer(d18:1/24:1); ceramide ratios 
Cer(d18:1/16:0)/Cer(d18:1/24:0), Cer(d18:1/20:0)/Cer(d18:1/24:0), Cer(d18:1/24:1)/Cer(d18:1/24:0)), 
and lactosylceramide (LacCer): LacCer(d18:1/18:0).  
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Plasma samples for measurement of lipid concentrations were available in 574 patients. Stored 
plasma samples were subjected to lipid extraction at Zora Biosciences, Finland. Briefly, Samples (10 μL) 
were spiked with known amounts of lipid-class specific, non-endogenous synthetic internal standards, 
D6-CE 18:0 (C/D/N Isotopes Inc.,Pointe-Claire, Quebec, Canada), Cer(d18:1/17:0) (Avanti Polar Lipids 
Inc., Alabaster, AL, USA)  and D3-LacCer(d18:1/16:0) (Matreya LLC, State College, Pennsylvania, USA). 
Lipid extraction was performed using chloroform (HPLC grade) (Rathburn Chemicals Ltd., Walkerburn, 
Scotland), methanol, and acetic acid (both LC-MS grade) (Sigma-Aldrich GmbH, Steinheim, Germany) 
(11). After lipid extraction, samples were reconstituted in chloroform: methanol (1:2, v/v) for 
sphingolipids analysis, and for molecular shotgun lipidomic analysis the extracts were further diluted 
with chloroform/methanol (1:2, v/v) containing 5 mM ammonium acetate. Quality control samples (QC) 
were prepared along with the actual samples for lipidomic analyses to monitor the extraction and MS 
performance. The intra-day (n=3) average coefficient of variation (CV) of sphingolipids and CE was less 
than or equal to 6% and inter-day (n=24 for Cer and LacCer; n=23 for CE except for CE(22:5) n=22) CV 
was less than 21% for both sphingolipids and CE.  
Sphingolipids were analyzed on a QTRAP® 5500 mass spectrometer (AB SCIEX, Concord, Canada) 
equipped with an ultra-high pressure liquid chromatography (UHPLC) system CTC PAL autosampler (Leap 
Technologies) and Accela 1250 Pump (Thermo Fisher Scientific., Massachusetts, United States). 
Chromatographic separation was performed on an Acquity BEH C18, 2.1 × 50 mm column with a particle 
size of 1.7 μm (Waters, Milford, MA). Mobile phases were 10 mM ammonium acetate in water with 
0.1% formic acid (solvent A) and 10 mM ammonium acetate in acetonitrile:isopropanol (4:3, v/v) 
containing 0.1% formic acid (solvent B). Lipids were separated with linear gradient from 75% B to 100% 
B in 15 min. Flow rate was 500 µL/min and column temperature was 60°C. Data was collected using 
multiple reaction monitoring in positive ion mode (12). Curtain gas was set at 25, ion spray voltage was 
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set at 5000 and ion source was heated to 400°C. Collision energy was optimized for each lipid class.  
Collision energy for Cer and LacCer was set to 40 and 45, respectively.  
Shotgun lipidomics was performed to monitor CE on a QTRAP® 5500 mass spectrometer (AB 
SCIEX, Concord, Canada) equipped with a robotic nanoflow ion source NanoMate HD (Advion, NY, USA) 
as described (11). CE were analyzed in positive ion mode using precursor ion scanning (PIS) of 369.35 
with collision energy 30 (13). Mass spectrometry data files were processed using MultiQuant™ 2.0.1 or 
LipidView™ 1.0 (AB SCIEX, Concord, Canada) (13).  Identified lipids were quantified by normalizing against 
their respective internal standard and volume of plasma used for the extraction. The limit of 
quantification (LOQ) for Cer, LacCer and CE in extract was 0.0004 µM, 0.0016 µM and 0.012 µM, 
respectively. All lipids monitored were within the LOQ. The LOQ was defined as the lowest point in the 
calibration curve with a signal-to-noise ratio greater than or equal to 10. 
 
Follow-up and study endpoints  
Clinical and vital status of patients were collected from medical charts, civil registries or by 
written or telephone contacts with the patients or relatives. All living patients participating in this study 
received a questionnaire, consisting of queries regarding the occurrence of MACE and re-admissions. For 
patients with adverse events, hospital discharge letters were obtained and treating physicians or 
institutions were contacted if necessary for additional information.  
The primary endpoint was the occurrence of MACE, comprising all-cause mortality, nonfatal 
ACS or unplanned coronary revascularization. The secondary endpoint comprised all-cause mortality and 
nonfatal ACS. ACS was defined as the clinical diagnosis of ST-segment elevation myocardial infarction 
(STEMI), non-STEMI or unstable angina pectoris (UAP) in accordance with the guidelines of the 
European society of Cardiology (14, 15). Unplanned coronary revascularization was defined as unplanned 
repeated PCI or unplanned coronary artery bypass grafting (CABG). The endpoints were adjudicated 
according to their definitions by a clinical events committee that was blinded to the lipid data. 
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Statistical analysis 
Categorical variables are presented as numbers and percentages. The distributions of continuous 
variables, including lipid concentrations and lipid ratios, were examined for normality by visual 
inspection of the histogram. Normally distributed continuous variables are presented as mean± standard 
deviation (SD). Non-normally distributed continuous variables (which included molecular lipid 
concentrations and lipid ratios) are presented as median (interquartile range [IQR]) and were 
logarithmically (Ln) transformed for further analyses.  
Patients lost during follow-up were considered at risk until the date of last contact, at which time-
point they were censored. Cox proportional hazards models were used to evaluate the associations 
between molecular lipids and clinical study endpoints. For patients who experienced more than 1 event, 
the first was considered. The results are presented as hazard ratios (HRs) per unit increase in (Ln-
transformed) molecular lipid concentrations or lipid ratios, with 95% confidence intervals (CIs). First, all 
analyses were performed univariably. In the multivariable analyses, gender, age, hypertension, 
hypercholesterolemia, diabetes mellitus and statin use were considered as potential confounders and were 
entered as covariates. These covariates were chosen for etiologic reasons and were based on existing 
literature (16). To evaluate whether the associations between molecular lipids and the clinical endpoints 
are independent of serum LDL cholesterol levels or serum non-HDL cholesterol levels, baseline serum 
LDL cholesterol level and baseline serum non-HDL cholesterol level were additionally (and 
consecutively) added into the multivariable models. Serum non-HDL level was calculated by subtracting 
HDL cholesterol level from total cholesterol level. In the full cohort, indication for CAG (ACS versus 
SAP) was also entered as a covariate. Interaction terms were added to the model to account for possible 
effect modification by indication for baseline CAG. Subsequently, analyses were stratified on indication 
for CAG. All data were analyzed with SPSS software (SPSS 23.0 IBM corp., Armonk, NY, USA). All 
statistical tests were two-tailed and p-values <0.05 were considered statistically significant. 
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Results 
Baseline characteristics 
The baseline clinical characteristics and the lipid concentrations of the ATHEROREMO study are 
summarized in Table 1 and Table 2. In total 574 patients were included. The mean age of the patients was 
61.5 years and 75% were men. A total of 55% patients were diagnosed with ACS (28% STEMI and 26% 
non-STEMI), and 46% patients with SAP. PCI was performed in 88% of the patients during the index 
procedure. Prior to the index procedure median serum LDL cholesterol level was 2.71 [IQR: 2.12- 3.54] 
mmol/l, median serum HDL cholesterol level was 1.04 [IQR: 0.87- 1.29] mmol/l, median serum non-
HDL cholesterol level was 3.23 [2.54- 4.00] mmol/l, and median serum triglyceride (TG) level was 1.27 
[IQR: 0.88- 1.83] mmol/l in the full cohort. ACS patients had significantly higher serum LDL cholesterol 
level ((median: 3.10 [IQR: 2.32- 3.87] mmol/l) p= < 0.001), higher serum non-HDL cholesterol level 
((median: 3.56 [2.81- 4.36]mmol/l) p = < 0.001) and lower serum TG level ((median= 1.15 [IQR: 0.77 - 
1.77] mmol/l) p = < 0.001)) compared with SAP patients (median: 2.37 [IQR: 1.94- 2.99] mmol/l, 2.83 
[2.35- 3.56] mmol/l and 1.41 [IQR: 1.05- 1.94] mmol/l, respectively). In addition, several other clinical 
characteristics were significantly different between the ACS patients and the SAP patients (Table 1). At 
the time of hospital admission 89% of the patients in the full cohort used statins.  
In Table 2 ACS patients had significantly higher plasma concentrations of CE 22:5; 
Cer(d18:1/16:0), Cer(d18:1/20:0), Cer(d18:1/24:0), Cer(d18:1/24:1), LacCer(d18:1/18:0) and 
Cer(d18:1/16:0)/Cer(d18:1/24:0) in the full cohort and in patients with no event (the non-MACE cohort) 
as compared with SAP patients. In patients with an event (MACE cohort), except plasma concentration of 
LacCer(d18:1/18:0), all of the above mentioned lipid species plasma concentrations were significantly 
higher in the ACS patients as compared with SAP patients. In addition, in ACS patients concentration of 
Cer(d18:1/16:0) was significant higher (p=0.054) in the MACE cohort as compared with the non-MACE 
cohort.  
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Molecular lipids concentrations and cardiovascular outcome 
In the full cohort (n=574) vital status was acquired for 572 patients (99.7%). The follow-up 
questionnaire assessing the occurrence of MACE was completed by 99% of the 574 patients. During a 
median follow-up time of 4.7 years (IQR: [4.2- 5.6]) years, a total of 155 patients (27%) experienced at 
least 1 MACE (primary endpoint). In the ACS group, 65 patients (21%) experienced MACE during long-
term follow-up, in the SAP group this was 90 patients (34%).  
The results for the associations between the molecular lipids concentrations and MACE are 
depicted in Figure 1 and Supplemental Table S1a. In multivariable analyses, after adjustment for cardiac 
risk factors, clinical presentation and statin use at baseline, Cer(d18:1/16:0) concentration (HR: 2.14; 95% 
CI [1.22- 3.76] per ln(pmol/mL) p= 0.008) and Cer(d18:1/24:1) concentration (HR: 1.64; 95% CI [1.00- 
2.68] per ln(pmol/mL) p= 0.049) were significantly associated with MACE. After additional adjustment 
for admission serum LDL cholesterol level, or serum non-HDL cholesterol level, only Cer(d18:1/16:0) 
concentration remained associated with MACE (HR: 2.16; 95% CI [1.09- 4.27] per ln(pmol/mL), p= 
0.027, and HR: 2.32; 95% CI [1.09- 4.96] per ln(pmol/mL, p= 0.030, respectively). 
The interaction term between Cer(d18:1/16:0) and indication for CAG was significant (p= 0.030) 
in the multivariable model. In ACS patients, higher Cer(d18:1/16:0) concentration was significantly 
associated with MACE, both in the uni- and multivariable model (HR adjusted for cardiac risk factors, 
statin use and non-HDL cholesterol level at baseline: 6.13; 95% CI [1.65 - 22.8]) per ln(pmol/mL) p= 
0.007) (Supplemental Table S2a). In SAP patients, HRs were closer to the null and did not reach 
statistical significance (Supplemental Table S2b). The interaction term between 
Cer(d18:1/16:0)/Cer(d18:1/24:0) and indication for CAG was also significant (p= 0.044). Its association 
with MACE only reached statistical significance, in univariable analysis in ACS patients (Supplemental 
table S2a).  
The incidence of MACE for Cer(d18:1/16:0) levels above and below the median are depicted in 
Figure 3. After adjustment for cardiac risk factors, statin use and baseline serum non-HDL cholesterol 
level, plasma Cer(d18:1/16:0) levels above vs below the median were significantly associated with 
 by guest, on Septem
ber 12, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
- 10 - 
 
MACE (HR: 2.63; 95% CI [1.44- 4.83], per ln(pmol/mL) p= 0.002) in ACS patients. In the full cohort 
and in SAP patients significant associations between plasma Cer(d18:1/16:0) levels above vs below the 
median and MACE could not be demonstrated ( Figure 3).  
Several lipid species displayed associations with the secondary endpoint (Figure 2 and 
Supplemental Table S1b); in univariable analysis, concentrations of Cer(d18:1/16:0), Cer(d18:1/20:0), 
Cer(d18:1/24:1), LacCer(d18:1/18:0), Cer(d18:1/16:0)/Cer(d18:1/24:0), Cer(d18:1/20:0)/Cer(d18:1/24:0) 
and Cer(d18:1/24:1)/Cer(d18:1/24:0) were significantly associated with the composite endpoint of death 
or nonfatal ACS (Supplemental table S1b). After multivariable adjustment for cardiac risk factors, 
indication for CAG, statin use at baseline and serum LDL cholesterol level, except LacCer(d18:1/18:0) 
concentration, all of the above mentioned lipid species remained significantly associated with the 
composite endpoint of death or nonfatal ACS. Results remained materially the same after adjusting the 
multivariable models for serum non-HDL cholesterol level instead of serum LDL cholesterol level. The 
interaction terms between indication for CAG and Cer(d18:1/16:0) (p= 0.006), Cer(d18:1/24:1) (p= 
0.025), Cer(d18:1/16:0)/Cer(d18:1/24:0) (p= 0.004) and Cer(d18:1/24:1)/Cer(d18:1/24:0) (p= 0.006) were 
significant on univariable and multivariable adjustment. All these associations were driven by the ACS 
patients (Supplemental table S3a and S3b). Interaction terms between indication for CAG and the 
remaining molecular lipids and lipid ratios did not reach statistical significance. 
 
Discussion 
We investigated the associations of ten previously identified high risk molecular lipid species and 
three ceramide ratios with clinical cardiovascular outcome during long-term follow-up in 581 patients. 
The main finding of our study was that higher Cer(d18:1/16:0) concentration and Cer(d18:1/24:1) 
concentration were significantly associated with MACE after multivariable adjustment for cardiac risk 
factors, clinical presentation and statin use at baseline. After additional adjustment for admission serum 
LDL cholesterol level or non-HDL cholesterol level, this association persisted only for Cer(d18:1/16:0) 
concentration. The latter association was driven by patients that presented with ACS. Another important 
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finding of this study was that several lipid species were significantly and independently associated with 
the secondary endpoint, comprising the composite of all-cause mortality or nonfatal ACS. Likewise, 
several of these associations were driven by patients presenting with ACS, in whom we also observed 
higher plasma lipid concentrations as compared to patients with SAP.  
Ceramides are a family of waxy lipid molecules and are composed of sphingosine and a fatty acid 
(17). They can be implicated in coronary artery disease through several mechanisms(3, 8). Ceramide is 
mainly produced through the SMase pathway, which breaks down sphingomyelin in the cell membrane 
and releases ceramides (17, 18). The production of ceramides can be increased by numerous 
cardiovascular risk factors such as oxidized-LDL and homocyteine (17). Moreover, inflammatory 
cytokines could also activate SMase and increase ceramide production mediated by increased reactive 
oxygen species (ROS) (17), which include H2O2, superoxide and hydroxyl radicals(17, 19). Ceramides 
can also act as signaling molecules regulating numerous cell responses and functions including the 
differentiation, proliferation, apoptosis and gene expression such as cytokines(17). Some of these roles of 
ceramides are associated with the molecular mechanisms of atherosclerosis and with plaque vulnerability 
(1, 17, 20).  
The molecular lipids species in this study were chosen from the LURIC lipidomic study (1). The 
LURIC lipidomic study compared 258 male CAD patients who died within 3 years of follow-up with 187 
matched control patients with CAD who did not die during the follow up. The chosen molecular lipid 
species were associated with CAD outcome at the p<0.05 level. Our present results in essence validate the 
previous LURIC study, albeit with a somewhat different endpoint that also contains non-fatal adverse 
cardiovascular events. Several molecular lipid species such as CE 14:0, CE 18:3, CE 20:4, CE 20:5, CE 
22:5, Cer(d18:1/24:0) were protective in the LURIC study but were not associated with clinical outcome 
in the present study. Conversely, Cer(d18:1/16:0), Cer(d18:1/20:0) and Cer(d18:1/24:1) were associated 
with mortality in the LURIC study and with clinical outcome in our present study. In a previous study 
ceramide long-chain-species were shown to mediate insulin resistance in mice and to be pro-apoptotic, 
whereas very-long-chain species were anti-apoptotic (21, 22). In our present study Cer(d18:1/16:0) and 
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Cer(d18:1/20:0) were independently associated with clinical outcome and more harmful than 
Cer(d18:1/24:0). Interestingly Cer(d18:1/24:1) behaved contrarily when compared with Cer(d18:1/24:0). 
The reason for this difference remains to be investigated in further studies. Furthermore, in the LURIC 
study LacCer(d18:1/18:0) was associated with mortality, whereas in the current study there was only an 
association with clinical outcome (Supplemental Table S1B) in the unadjusted model. Based on previous 
observations LacCer (a glycosphingolipid) and other glucosylceramides appear to influence the 
atherogenic process in the  atherosclerotic plaque by suppressing the production of macrophage 
apolipoprotein E leading to an accumulation of cholesterol in macrophage foam cells (19, 23). Moreover, 
in aortic smooth muscle cell LacCer is activated by oxidized-LDL and subsequently, LacCer enhances the 
activity of nicotinamide adenine dinucleotide phosphate oxidase to generate superoxide radicals which in 
turn mediate p44MAPK activation to enhance nuclear transcription factor expression and to stimulate the 
proliferation of smooth muscle cells, thereby contributing to atherosclerosis(2, 23). Altogether, as 
increased levels of LacCer mediate plaque formation, a relationship between LacCer and cardiovascular 
clinical outcome is to be expected. However in our study there was no independent association. Further 
studies are needed to establish the biological mechanisms of LacCer in CAD patients.  
In our previous report on the current study population, Cer(d18:1/16:0) was an independent 
predictor of MACE during 1 year follow-up, and the three ceramide ratios were independent predictors of 
the composite endpoint of death or nonfatal ACS (20). Our current study confirms and extends the 
findings of our previous lipidomics analyses with shorter term follow-up (20).  
Associations of lipids with incident acute MACE (all-cause mortality and nonfatal ACS) were 
more prominent than those with ‘overall’ MACE. Associations were also more prominent in patients 
presenting with ACS than in those with SAP; although in the stratified analyses numbers of MACE were 
limited (90 in SAP patients and 65 in ACS patients), which may have influenced statistical significance, 
hazard ratios in SAP patients were also clearly closer to the null and interaction terms were significant. 
These findings are in line with pathophysiological insights from earlier studies. Patients with ACS have 
been shown to exhibit an increased pro-inflammatory and oxidative state compared to SAP patients (24, 
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25). This state even persists after stabilization (26, 27). High lipid plasma concentrations induce oxidative 
stress mediated by ROS (24, 28) and herewith further increase the risk of incident ACS. Furthermore, in 
ACS patients, so-called high-risk or vulnerable plaques have been shown to be more frequently present, 
which are more likely to lead to plaque rupture and thus to acute cardiac events (29, 30). These plaques 
have been shown to carry large lipid cores, and have been associated with high circulating lipid levels 
(20, 31).  
In the last decade lipid species have received considerable attention as potential biomarkers in 
several lipid-related diseases (9). Furthermore, several molecular lipid species have been associated with 
the composition of atherosclerotic plaque (20) and with cardiovascular events during short-term follow-up 
(20, 32). However, clinical studies in patients with CAD on the association of lipid molecular species 
with cardiovascular outcome during long term follow-up are scarce. Laaksonen et al. (32) examined 
several ceramides and ceramide ratios in the Corogene cohort (80 stable CAD patients who died and 80 
matched controls, 2.5 years follow-up), as well as in the BECAC cohort (1580 stable CAD patients, 81 of 
whom died during 4.6 years follow-up). In both cohorts Cer(d18:1/16:0), Cer(d18:1/18:0), 
Cer(d18:1/24:1), Cer(d18:1/16:0)/Cer(d18:1/24:0), Cer(d18:1/18:0)/Cer(d18:1/24:0) and 
Cer(d18:1/24:1)/Cer(d18:1/24:0) were associated with cardiovascular death. Although Laaksonen et al. 
only examined cardiovascular death, and not (acute) MACE, the results with regard to the corresponding 
ceramides and ceramide ratios were in line with our results, even though the associations in our study 
were driven by patients presenting with ACS. Havulinna et al. (3), in the FINRISK cohort, measured 4 
circulating ceramides in a healthy population, and within this population they examined a subgroup with 
prevalent or incident MACE. In these 396 patients, plasma Cer(d18:1/16:0) and Cer(d18:1)/24:1) 
concentrations were independent predictors of recurrent MACE (n=226) or fatal recurrent MACE (n=70) 
during a follow-up of 13 years. These results were in line with ours, although in our study the association 
between Cer(d18:1/24:1) and MACE was not independent of LDL or non-HDL cholesterol level. 
Conversely, its association with the secondary endpoint (nonfatal ACS or death) was independent of LDL 
or non-HDL cholesterol level. Other studies on long-term prognostic value of lipidomics have mostly 
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used healthy populations. In the Bruneck study, Stegemann et al.(33) analyzed the association of 135 lipid 
species (including CEs) with incident cardiovascular disease (CVD) during 10-year follow-up in a 
prospective population-based survey. They demonstrated significant associations for 28 lipids. Among 
these lipid species, 3 were most informative for CVD risk: TAG(54:2), CE(16:1) and PE(36:5). The 
results with regard to the CEs that were also measured in this study were in line with our results, i.e. no 
significant associations were found. Moreover, Alshehry et al. (2) examined the prognostic value of 310 
plasma lipid species (including CEs and CERs) for cardiovascular risk stratification in a case-cohort of 
3779 individuals with diabetes mellitus that included 698 patients with cardiovascular events and 355 
patients with cardiovascular death. Multiple lipid species were significantly associated with 
cardiovascular events and cardiovascular death. In line with our study, a significant association was found 
between Cer(d18:1/24:1) and death. In contrast to our study, no association was found between plasma 
Cer(d18:1/16:0) and cardiovascular outcome. This may possibly be explained by differences in the study 
populations; in particular, the patients studied by Alshehry et al. were diagnosed with diabetes mellitus 
and had ≥ 1 additional cardiovascular risk factors. For the other lipid species, no significant associations 
were found. 
Some limitations of this study need to be acknowledged. First, this study is an observational 
cohort study. Despite using multivariable analysis to adjust for possible confounders that may be related 
to the study outcomes, we cannot exclude the possibility of residual confounding. Secondly, a large 
proportion of the subjects were on lipid lowering medication, which will influence the plasma lipid 
concentrations in these individuals. However, all multivariable analyses were adjusted for statin use.  
In conclusion, in patients with established CAD, plasma Cer(d18:1/16:0) was associated with 
MACE during a median follow-up time of 4.7 years, independently from established cardiac factors, 
statin use and serum LDL or non-HDL cholesterol level. Furthermore, after multivariable adjustment, 
concentrations of Cer(d18:1/16:0), Cer(d18:1/20:0), Cer(d18:1/24:1) and all ceramide ratios were 
associated with the secondary endpoint, comprising the composite of all-cause mortality or nonfatal ACS. 
Our results support the hypothesis that ceramide plasma concentrations and ratios predict long-term 
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cardiovascular outcome and therefore circulating molecular lipids may further improve risk stratification 
of CAD patients.  
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Tables 
Table 1. Clinical characteristics 
  
 
* A significant stenosis was defined as a stenosis ≥ 50% of the vessel diameter by visual assessment of the coronary angiogram.  
Continuous variables are presented as mean± standard deviation (SD) or median [IQR]. Categorical variables are presented in 
numbers (n) and percentages (%).  
P-value was obtained from student’s t-test. 
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CAG, coronary 
angiography; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; MI, myocardial infarction; 
PCI, percutaneous coronary intervention; SAP, stable angina pectoris; TG, triglycerides. 
 
 
Clinical characteristics 
Total 
(n=574) 
ACS patients 
(n=313) 
SAP patients 
(n= 261) 
p-value 
Age, years, mean ± SD 61.5 ± 11.3 59.7 ± 11.9 63.6 ± 10.3 <0.001 
Male, n (%) 432 (75) 230 (74) 202 (77) 0.279 
Diabetes Mellitus, n (%) 97 (17) 40 (13) 57 (22) 0.004 
Hypertension, n (%) 298 (52) 137 (44) 161 (62) <0.001 
Hypercholesterolemia, n (%) 318 (55) 138 (44) 180 (69) <0.001 
Smoking, n (%) 166 (29) 116 (37) 50 (19) <0.001 
Positive family history of CAD, n (%) 298 (52) 145 (46) 153 (59) 0.004 
Previous MI, n (%) 184 (32) 80 (26) 104 (40) <0.001 
Previous PCI, n (%) 184 (32) 57 (18) 127 (49) <0.001 
Previous CABG, n (%) 18 (3) 7 (2) 11 (4) 0.176 
Previous stroke, n (%) 26 (5) 11 (4) 15 (6) 0.200 
Peripheral artery disease, n (%) 35 (6) 11 (4) 24 (9) 0.005 
History of heart failure, n (%) 19 (3) 6 (2) 13 (5) 0.041 
Serum LDL cholesterol, mmol/L 2.71 [2.12-3.54] 3.10 [2.32-3.87] 2.37 [1.94-2.99] <0.001 
Serum HDL cholesterol, mmol/L 1.04 [0.87-1.29] 1.05 [0.87-1.27] 1.03 [0.86-1.30] 0.80 
Serum non-HDL levels, mmol/L 3.23 [2.54-4.00] 3.56 [2.81-4.36] 2.83 [2.35-3.56] <0.001 
Serum TG mmol/L 1.27 [0.88-1.83] 1.15 [0.77-1.77] 1.41 [1.05-1.94] <0.001 
Statin use at baseline, n (%) 508 (89%) 308 (98%) 235 (90%) 0.499 
Procedural characteristics     
Indication for CAG     
ACS, n (%) 313 (55) 313 (100) 0 (0)  
           STEMI, n (%) 162 (28) 162 (52) 0 (0)  
           Non-ST-elevation, n (%) 151 (26) 151 (48) 0 (0)  
Stable angina pectoris, n (%)  261 (46) 0 (0) 261 (100)  
PCI performed, n (%) 505 (88) 291 (93) 214 (82)  
Coronary artery disease *     
No significant stenosis, n (%) 42 (7) 18 (6) 24 (9)  
1-vessel disease, n (%) 304 (53) 172 (55) 132 (51)  
2-vessel disease, n (%) 167 (29) 88 (28) 79 (30)  
3-vessel disease, n (%)   61 (11) 35 (11) 26 (10)  
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Table 2. Lipid concentrations in the full cohort, MACE cohort and non-MACE cohort 
* Patients with a major adverse cardiac event 
** Patients with no major adverse cardiac event 
Concentrations are presented in μM as median [IQR].  
 
Lipid concentrations in the full cohort 
Total 
(n=574) 
ACS patients 
(n=313) 
SAP patients 
(n= 261) 
p-value 
CE 14:0, pmol/µl 21.7 [15.9-28.1] 22.9 [16.5-30.5] 21.2 [15.4-26.8] 0.008 
CE 18:3, pmol/µl 70.3 [51.8-90.7] 72.3 [53.6-99.5] 66.1 [50.3-85.2] 0.003 
CE 20:4, pmol/µl 386 [317-457] 394 [324-453] 374 [307-471] 0.31 
CE 20:5, pmol/µl 49.1 [36.3-72.6] 49.2 [36.4-72.1] 49.0 [35.9-74.7] 0.69 
CE 22:5, pmol/µl 2.65 [2.00-3.62] 2.81 [2.12-3.77] 2.53 [1.90-3.40] 0.037 
Cer(d18:1/16:0) pmol/µl 0.12 [0.10-0.15] 0.13 [0.11-0.17] 0.11 [0.09-0.13] <0.001 
Cer(d18:1/20:0) pmol/µl 0.11 [0.09-0.15] 0.12 [0.10-0.16] 0.11 [0.08-0.13] <0.001 
Cer(d18:1/24:0) pmol/µl 5.98 [4.72-7.49] 6.43 [5.00-8.07] 5.65 [4.49-6.61] <0.001 
Cer(d18:1/24:1) pmol/µl 1.79 [1.42-2.25] 1.89 [1.52-2.44] 1.67 [1.35-2.05] <0.001 
LacCer(d18:1/18:0) pmol/µl 0.13 [0.10-0.16] 0.13 [0.11-0.16] 0.12 [0.10-0.15] 0.001 
Cer(d18:1/16:0)/Cer(d18:1/24:0)  pmol/µl 0.020 [0.018-0.024] 0.021 [0.018-0.025] 0.020 [0.017-0.023] 0.001 
Cer(d18:1/20:0)/Cer(d18:1/24:0)  pmol/µl 0.019 [0.016-0.024] 0.019 [0.015-0.024] 0.019 [0.016-0.023] 0.62 
Cer(d18:1/24:1)/Cer(d18:1/24:0)  pmol/µl 0.31 [0.26-0.36] 0.31 [0.26-0.36] 0.31 [0.26-0.36] 0.65 
Lipid concentrations in the MACE 
cohort* 
Total 
(n=155) 
ACS patients 
(n=65) 
SAP patients 
(n=90) 
P-value 
CE 14:0, pmol/µl 22.6 [15.7-27.1] 21.7 [15.5-30.3] 22.7 [15.7-26.6] 0.67 
CE 18:3, pmol/µl 67.9 [51.2-90.3] 70.3 [52.8-103] 66.9 [50 -84.1] 0.17 
CE 20:4, pmol/µl 381 [310-445] 381 [310-432] 379 [310-447] 0.95 
CE 20:5, pmol/µl 52.4 [37.4-74.5] 52.6 [38.4-76.3] 50.9 [36.6-74.4] 0.73 
CE 22:5, pmol/µl 2.57 [1.86-3.71] 2.61 [2.04-3.97] 2.51 [1.80-3.45] 0.065 
Cer(d18:1/16:0) pmol/µl 0.12 [0.10-0.16] 0.15 [0.11-0.17] 0.11 [0.09-0.13] <0.001 
Cer(d18:1/20:0) pmol/µl 0.11 [0.09-0.16] 0.13 [0.10-0.17] 0.11 [0.08-0.14] 0.011 
Cer(d18:1/24:0) pmol/µl 5.86 [4.65-7.48] 6.44 [5.02-8.10] 5.66 [4.54-6.58] 0.063 
Cer(d18:1/24:1) pmol/µl 1.78 [1.35-2.36] 2.10 [1.66-2.84] 1.62 [1.33-2.13] 0.008 
LacCer(d18:1/18:0) pmol/µl 0.13 [0.10-0.16] 0.14 [0.10-0.18] 0.13 [0.10-0.16] 0.137 
Cer(d18:1/16:0)/Cer(d18:1/24:0)  pmol/µl 0.021 [0.018-0.025] 0.022 [0.019-0.027] 0.019 [0.017-0.024] 0.006 
Cer(d18:1/20:0)/Cer(d18:1/24:0)  pmol/µl 0.020 [0.016-0.025] 0.020 [0.016-0.024] 0.020 [0.015-0.025] 0.504 
Cer(d18:1/24:1)/Cer(d18:1/24:0)  pmol/µl 0.31 [0.27-0.37] 0.33 [0.27-0.36] 0.31 [0.26-0.37] 0.222 
Lipid concentrations in the non-MACE 
cohort** 
Total 
(n=411) 
ACS patients 
(n=242) 
SAP patients 
(n=169) 
P-value 
CE 14:0, pmol/µl 21.5 [15.8-28.7] 23 [16.5-30.5] 20.7 [15.3-27] 0.007 
CE 18:3, pmol/µl 70.5 [51.7-91.3] 73.8 [53.5-99] 66 [50.3 -86.4] 0.011 
CE 20:4, pmol/µl 391 [321-467] 397 [310-432] 374 [304-476] 0.272 
CE 20:5, pmol/µl 49.1 [35.6-70.5] 49.2 [35.5-70.7] 47.5 [35.6-70] 0.575 
CE 22:5, pmol/µl 2.69 [2.04-3.58] 2.79 [2.12-3.70] 2.54 [1.92-3.40] 0.041 
Cer(d18:1/16:0) pmol/µl 0.12 [0.10-0.15] 0.13 [0.11-0.16] 0.11 [0.09-0.13] <0.001 
Cer(d18:1/20:0) pmol/µl 0.12 [0.09-0.14] 0.12 [0.09-0.15] 0.11 [0.08-0.13] <0.001 
Cer(d18:1/24:0) pmol/µl 6 [4.75-7.47] 6.39 [4.97-8.07] 5.64 [4.49-6.64] <0.001 
Cer(d18:1/24:1) pmol/µl 1.78 [1.35-2.36] 1.86 [1.51-2.33] 1.68 [1.35-2.04] <0.001 
LacCer(d18:1/18:0) pmol/µl 0.13 [0.10-0.16] 0.13 [0.11-0.16] 0.12 [0.10-0.15] 0.001 
Cer(d18:1/16:0)/Cer(d18:1/24:0)  pmol/µl 0.021 [0.018-0.025] 0.021 [0.018-0.024] 0.020 [0.017-0.023] 0.017 
Cer(d18:1/20:0)/Cer(d18:1/24:0)  pmol/µl 0.020 [0.016-0.025] 0.019 [0.015-0.024] 0.019 [0.016-0.023] 0.60 
Cer(d18:1/24:1)/Cer(d18:1/24:0)  pmol/µl 0.31 [0.27-0.37] 0.30 [0.25-0.36] 0.31 [0.26-0.36] 0.77 
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P-value was obtained from student’s t-test for difference in ln-transformed mean lipid concentration. 
ACS, acute coronary syndrome; CE, cholesteryl ester; Cer, ceramide; LacCer, lactosylceramide; MACE, major adverse cardiac 
events SAP, stable angina pectoris. 
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Figures 
 
Figure 1. Association of plasma concentrations of molecular lipid species with MACE.  
The results are presented as hazard ratios (HRs) per unit increase in (Ln-transformed) molecular lipid 
concentrations or lipid ratios, with 95% confidence intervals (CI). 
CE, cholesteryl ester; Cer, ceramide; LacCer, lactosylceramide; MACE, major adverse cardiac events.                                                                                                                                                                    
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Figure 2. Association of plasma concentrations of molecular lipid species with non-fatal ACS or 
death.  
The results are presented as hazard ratios (HRs) per unit increase in (Ln-transformed) molecular lipid 
concentrations or lipid ratios, with 95% confidence intervals (CI). 
ACS, acute coronary syndrome CE, cholesteryl ester; Cer, ceramide; LacCer, lactosylceramide.                                                                                                                                                                    
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Figure 3. Association of plasma concentrations of Cer (d18:1/16:0) with MACE in the full cohort 
and in patients with ACS or SAP.  
The results are presented as Hazard Ratios (HRs) for Cer(d18:1/16:0) above versus below the median, 
with 95% confidence intervals (CI).   
ACS, acute coronary syndrome; Cer, ceramide; MACE, major adverse cardiac events; SAP, stable angina 
pectoris.                                                                                                                                                              
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